Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Gastroenterol Hepatol

Retrieve available abstracts of 76 articles:
HTML format

Single Articles

    November 2022
  1. VICENS DG, Belinchon MR, Mateu PN, Elena Pejenaute Labari M, et al
    Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) survey on the management of patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022 Nov 16:S0210-5705(22)00269.
    PubMed     Abstract available

  2. QUERA R, Nunez P, Sicilia B, Flores L, et al
    Corticosteroids in Inflammatory Bowel Disease: Are they still a therapeutic option?
    Gastroenterol Hepatol. 2022 Nov 11. pii: S0210-5705(22)00263.
    PubMed     Abstract available

  3. PARRA-IZQUIERDO V, Frias-Ordonez JS, Marquez JR, Juliao-Banos F, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Gastroenterol Hepatol. 2022 Nov 10. pii: S0210-5705(22)00266.
    PubMed     Abstract available

  4. JULIAO-BANOS F, Osorio L, Carvajal J, Mosquera-Klinger G, et al
    Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry.
    Gastroenterol Hepatol. 2022;45:690-696.
    PubMed     Abstract available

  5. HERNANDEZ CAMBA A, Ramos L, Madrid Alvarez MB, Perez-Mendez L, et al
    Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
    Gastroenterol Hepatol. 2022;45:668-676.
    PubMed     Abstract available

  6. DEL HOYO J, Millan M, Garrido-Marin A, Nos P, et al
    Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
    Gastroenterol Hepatol. 2022;45:697-705.
    PubMed     Abstract available

  7. LADRON ABIA P, Minguez Sabater A, Saez Gonzalez E, Beltran Niclos B, et al
    Rescue therapy with oral cyclosporine after use of ustekinumab in ulcerative colitis resistant to multiple treatments.
    Gastroenterol Hepatol. 2022;45:735-736.

    October 2022
  8. CONSTANZA BAY M, Paulina Nunez F, Quera R, Yarur AJ, et al
    Current perspectives on pediatric inflammatory bowel disease focusing on Transitional care management. What should we consider?"
    Gastroenterol Hepatol. 2022 Oct 12. pii: S0210-5705(22)00229.
    PubMed     Abstract available

  9. GELY C, Gordillo J, Bertoletti F, Gonzalez-Munoza C, et al
    Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2022 Oct 12. pii: S0210-5705(22)00231.
    PubMed     Abstract available

  10. LADRON ABIA P, Alonso N, Minguez Sabater A, Gimeno Torres M, et al
    The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
    Gastroenterol Hepatol. 2022;45:614-620.
    PubMed     Abstract available

  11. WAH-SUAREZ MI, Vazquez MAM, Bosques-Padilla FJ
    Inflammatory bowel disease: The role of commensal microbiome in immune regulation.
    Gastroenterol Hepatol. 2022;45:626-636.
    PubMed     Abstract available

    September 2022
  12. NUNEZ L, Mesonero F, Rodriguez de Santiago E, Die J, et al
    High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified.
    Gastroenterol Hepatol. 2022 Sep 14. pii: S0210-5705(22)00216.
    PubMed     Abstract available

  13. LATRAS-CORTES I, Alvarez PS, Prada MG, Sanz NC, et al
    Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: clinical practice data.
    Gastroenterol Hepatol. 2022 Sep 13. pii: S0210-5705(22)00211.

    August 2022
  14. ALGABA A, Guerra I, Castro S, Bermejo F, et al
    SARS-CoV-2 infection in patients with inflammatory bowel disease in the second-third wave and its comparison with data of first wave of pandemic.
    Gastroenterol Hepatol. 2022;45:572-573.

  15. ROMERO RK, Magro DO, Queiroz NSF, Damiao AOMC, et al
    Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Gastroenterol Hepatol. 2022;45:499-506.
    PubMed     Abstract available

    May 2022
  16. ROIG CA, Ferrer CS, Garcia JLR, Cordon JP, et al
    "Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease".
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00156.
    PubMed     Abstract available

  17. ALGABA A, Romero S, Granja A, Garza D, et al
    Serological Response To Vaccines Against Sars-Cov-2 In Patients With Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00154.
    PubMed     Abstract available

  18. LATRAS CORTES I, Sierra-Ausin M
    Tacrolimus plus ustekinumab in refractory ulcerative colitis.
    Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00145.

  19. MARIA SR, Jesus B, Luis FS, Lara A, et al
    Incidence, and natural history of inflammatory bowel disease in Castilla y Leon: prospective and multicenter epidemiological study.
    Gastroenterol Hepatol. 2022 May 12. pii: S0210-5705(22)00139.
    PubMed     Abstract available

  20. SURIA C, Bosca-Watts MM, Navarro P, Tosca J, et al
    Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
    Gastroenterol Hepatol. 2022;45:383-389.
    PubMed     Abstract available

  21. RAMOS L, Ramos-Rodriguez J, Barreda R, Gutierrez-Nicolas F, et al
    Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45:335-341.
    PubMed     Abstract available

    April 2022
  22. MERINO GALLEGO E, Gallardo Sanchez F
    Prevalence of extra-intestinal manifestations, risk factors and therapeutic risk factors and therapeutic management in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45 Suppl 1:4-5.

  23. MARQUES-CAMI M, Garcia-Guinon A, Garreta J, Volta T, et al
    A 61-year-old patient with Crohn's disease and severe postoperative recurrence responding to JAK inhibitor ruxolitinib for polycythemia vera treatment.
    Gastroenterol Hepatol. 2022;45 Suppl 1:16-17.

  24. ESTEBANEZ FERRERO B, Ruiz Pardo J, Velasco Albendea FJ, Vidana Marquez E, et al
    Tuberculosis mimicking Crohn's disease and respiratory infection by COVID-19.
    Gastroenterol Hepatol. 2022;45 Suppl 1:13-15.

    March 2022
  25. NUNEZ F P, Quera R, Bay C, Thomson P, et al
    Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
    Gastroenterol Hepatol. 2022;45:223-230.
    PubMed     Abstract available

  26. MINGUEZ SABATER A, Conde Amiel I, Ladron Abia P, Martinez Delgado S, et al
    Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: Experience of a transplant center in the Mediterranean basin.
    Gastroenterol Hepatol. 2022;45:177-185.
    PubMed     Abstract available

  27. MARIN-JIMENEZ I, Acosta MB, Esteve M, Castro-Laria L, et al
    Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
    Gastroenterol Hepatol. 2022;45:165-176.
    PubMed     Abstract available

    February 2022
  28. REFAIE E, Garcia Mateo S, Martinez Dominguez SJ, Gargallo-Puyuelo CJ, et al
    Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45:114-122.
    PubMed     Abstract available

  29. ROCHA HC, Vilela EG
    Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Gastroenterol Hepatol. 2022;45:83-90.
    PubMed     Abstract available

    January 2022
  30. MEARIN F, Sans M, Balboa A
    Relevance and needs of Irritable Bowel Syndrome (IBS): comparison with Inflammatory Bowel Disease (IBD).
    Gastroenterol Hepatol. 2022 Jan 17. pii: S0210-5705(21)00332.
    PubMed     Abstract available

  31. YEBRA CARMONA J, Poza Cordon J, Suarez Ferrer C, Martin Arranz E, et al
    Correlation between endoscopy and intestinal ultrasound for the evaluation of postoperative recurrence of Crohn's disease.
    Gastroenterol Hepatol. 2022;45:40-46.
    PubMed     Abstract available

  32. ROJAS-FERIA M, Rodriguez-Fernandez M, Castro-Fernandez M, Suarez-Garcia E, et al
    Vedolizumab-induced cholestatic liver injury.
    Gastroenterol Hepatol. 2022;45:64-65.

    December 2021
  33. ZAVALA-SOLARES MR, Salazar-Salas L, Yamamoto-Furusho JK
    Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2021;44:711-718.
    PubMed     Abstract available

    November 2021
  34. ZHANG X, Ma L, Zhang C, Hou B, et al
    Silencing LncRNA-DANCR attenuates inflammation and DSS-induced endothelial injury through miR-125b-5p.
    Gastroenterol Hepatol. 2021;44:644-653.
    PubMed     Abstract available

    October 2021
  35. CALVET X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, et al
    Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Gastroenterol Hepatol. 2021;44:587-598.
    PubMed     Abstract available

    August 2021
  36. FERREIRO-IGLESIAS R, Hernandez-Camba A, Serrano Labajos R, Rodriguez-Lago I, et al
    SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project.
    Gastroenterol Hepatol. 2021 Aug 25. pii: S0210-5705(21)00246.
    PubMed     Abstract available

  37. LIDON RV, Lopez SG, Roche PC, Miguel Boudet Barraca J, et al
    Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient s perspective: IBD-control, EII-control.
    Gastroenterol Hepatol. 2021 Aug 21. pii: S0210-5705(21)00243.
    PubMed     Abstract available

  38. RODRIGUEZ-LAGO I, Mesonero F, Hijos-Mallada G, Canas M, et al
    Gastroenterol Hepatol. 2021 Aug 13. pii: S0210-5705(21)00227.
    PubMed     Abstract available

  39. GENE M, Alguersuari A, Pons F, Minambres C, et al
    Serrated epithelial lesion with dysplasia as a precursor to small bowel carcinoma associated with Crohn's disease.
    Gastroenterol Hepatol. 2021;44:489-490.

    July 2021
  40. LORAS C, Manosa M, Andujar X, Sanchiz V, et al
    Recommendations of the spanish group on crohn's disease and ulcerative colitis (geteccu) on the treatment of strictures in crohn's disease.
    Gastroenterol Hepatol. 2021 Jul 15. pii: S0210-5705(21)00219.
    PubMed     Abstract available

    June 2021
  41. HIJOS-MALLADA G, Sostres C, Gomollon F
    NSAIDs, gastrointestinal toxicity and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2021 Jun 19. pii: S0210-5705(21)00201.
    PubMed     Abstract available

  42. FORTUNY BAUZA M, Canete Pizarro F, Calm Salvans A, Calafat Sard M, et al
    Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00188.

  43. GONZALEZ-MUNOZA C, Briones J, Sang Park H, Garcia-Planella E, et al
    Marginal zone lymphoma under anti-TNF treatment in Crohn disease.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00193.

  44. JULIAO-BANOS F, Arrubla M, Osorio L, Camargo J, et al
    Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Gastroenterol Hepatol. 2021;44:398-404.
    PubMed     Abstract available

    May 2021
  45. PEREZ DE ARCE E, Quera R, Beltran CJ, Madrid AM, et al
    Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00143.
    PubMed     Abstract available

  46. SEMPERE L, Bernabeu P, Cameo J, Gutierrez A, et al
    Evolution of the emotional impact in patients with early Inflammatory Bowel Disease during and after Covid-19 lockdown.
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00145.

    April 2021
  47. GONZALEZ AE, Castillejo ON, Sainz IF, Lopez-Garcia A, et al
    Use of capsule endoscopy in Inflammatory Bowel Disease in clinical practice in Spain. Results from a national survey.
    Gastroenterol Hepatol. 2021 Apr 16. pii: S0210-5705(21)00110.
    PubMed     Abstract available

  48. NUNEZ F P, Quera R, Sepulveda E, Simian D, et al
    Pregnancy in Inflammatory Bowel Disease: Experience of a Chilean cohort.
    Gastroenterol Hepatol. 2021;44:277-285.
    PubMed     Abstract available

  49. DIAZ ALCAZAR MDM, Martin-Lagos Maldonado A, Garcia-Consuegra Ruiz-Aragon FM, Herrera Mercader MDC, et al
    Liver abscesses as an initial manifestation of Crohn's disease.
    Gastroenterol Hepatol. 2021;44:310-311.

  50. DE LOS MOZOS RUANO A, Casas Deza D, Calvo Galindo R, Solana Hidalgo MP, et al
    Methotrexate pneumonitis in a patient with Crohn's disease, during the COVID pandemic: An unusual clinical case and review of the literature.
    Gastroenterol Hepatol. 2021;44:302-303.

  51. HALLOUCH TOUTOUH S, Lazaro Saez M, Hernandez Martinez A
    Ustekinumab for prevention of postoperative recurrence: Our clinical experience.
    Gastroenterol Hepatol. 2021;44:296-297.

    February 2021
  52. SICILIA B, Vicente R, Arias L, Echarri A, et al
    Recommendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2021 Feb 13. pii: S0210-5705(21)00043.
    PubMed     Abstract available

  53. CRISTINA SF, Angeles RRM, Maria SA, Luis RGJ, et al
    Nutricional Habits In Patients With Inflammatory Bowel Disease: Perception Of Patients And Health Professionals.
    Gastroenterol Hepatol. 2021 Feb 2. pii: S0210-5705(21)00014.

  54. RODRIGUEZ C, Elosua A, Prieto C, Perez E, et al
    COLECTOMY RATE IN ULCERATIVE COLITIS 15 YEARS AFTER DIAGNOSIS: Results from the 2001-2003 Navarra cohort.
    Gastroenterol Hepatol. 2021 Feb 2. pii: S0210-5705(21)00003.
    PubMed     Abstract available

  55. PENNA FGC, Rosa RM, Pereira FH, Cunha PFS, et al
    Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
    Gastroenterol Hepatol. 2021;44:87-95.
    PubMed     Abstract available

    January 2021
  56. NAVARRO-CORREAL E, Borruel N, Robles V, de Guise CH, et al
    Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease.
    Gastroenterol Hepatol. 2021 Jan 27. pii: S0210-5705(21)00005.
    PubMed     Abstract available

  57. BLASCO PATINO F, Nicolae MV, Navarro E
    Acute submandibular sialadenitis in a patient with Crohn's disease being treated with infliximab.
    Gastroenterol Hepatol. 2021;44:49-50.

    December 2020
  58. MUNOZ F, Ripolles T, Poza Cordon J, de Las Heras Paez de la Cadena B, et al
    Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of abdominal ultrasound in inflammatory bowel disease.
    Gastroenterol Hepatol. 2020 Dec 11. pii: S0210-5705(20)30214.
    PubMed     Abstract available

    November 2020
  59. RUBIANO MR, Medina GR, Perez-Riveros ED, Panqueva RDPL, et al
    Proctitis is not always ulcerative colitis.
    Gastroenterol Hepatol. 2020 Nov 25. pii: S0210-5705(20)30441.

  60. QUERA R, Simian D, Flores L, Ibanez P, et al
    Gastroenterol Hepatol. 2020 Nov 21. pii: S0210-5705(20)30438.

  61. QUERA R, Pizarro G, Simian D, Ibanez P, et al
    Impact of COVID-19 on a cohort of patients with inflammatory bowel disease at a specialised centre in Chile.
    Gastroenterol Hepatol. 2020 Nov 20. pii: S0210-5705(20)30431.

  62. LADRON ABIA P, Alcala Vicente C, Martinez Delgado S, Bastida Paz G, et al
    Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
    Gastroenterol Hepatol. 2020 Nov 13. pii: S0210-5705(20)30364.

  63. MINGUEZ SABATER A, Martinez Delgado S, Ladron Abia P, Bastida G, et al
    Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
    Gastroenterol Hepatol. 2020 Nov 11. pii: S0210-5705(20)30378.

  64. LUCAS RAMOS J, Suarez Ferrer C, Poza Cordon J, Sanchez Azofra M, et al
    Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
    Gastroenterol Hepatol. 2020 Nov 7. pii: S0210-5705(20)30387.
    PubMed     Abstract available

  65. PEREZ DE ARCE E, Quera R, Nunez P, Simian D, et al
    Management of acute severe ulcerative colitis in chile: Experience of a multidisciplinary team.
    Gastroenterol Hepatol. 2020 Nov 6. pii: S0210-5705(20)30400.

    October 2020
  66. QUERA R, Simian D, Nunez P, Flores L, et al
    Are patients with inflammatory bowel disease receiving adequate immunisation?
    Gastroenterol Hepatol. 2020 Oct 29. pii: S0210-5705(20)30303.
    PubMed     Abstract available

  67. EZQUERRA A, Resina E, Montes A, Alvarez-Male T, et al
    Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis.
    Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30377.

  68. NUNEZ P, Garcia Mateo S, Quera R, Gomollon F, et al
    Inflammatory bowel disease and the risk of cardiovascular diseases.
    Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30375.
    PubMed     Abstract available

  69. NUNEZ F P, Quera R, Simian D, Flores L, et al
    Infliximab in inflammatory bowel disease. Is premedication necessary?
    Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30362.
    PubMed     Abstract available

  70. NUNEZ F P, Mahadevan U, Quera R, Bay C, et al
    Treat-to-target approach in the management of inflammatory Bowel disease.
    Gastroenterol Hepatol. 2020 Oct 15. pii: S0210-5705(20)30318.
    PubMed     Abstract available

  71. LOPEZ GONZALEZ J, Hernandez Martinez A, Lazaro Saez M, Vega Saenz JL, et al
    Experience with tofacitinib in patients with refractary ulcerative colitis.
    Gastroenterol Hepatol. 2020 Oct 10. pii: S0210-5705(20)30309.

  72. GARCIA-ALANIS M, Quiroz-Casian L, Castaneda-Gonzalez H, Arguelles-Castro P, et al
    Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease.
    Gastroenterol Hepatol. 2020 Oct 8. pii: S0210-5705(20)30304.
    PubMed     Abstract available

  73. DEL HOYO J, Aguas M
    Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?
    Gastroenterol Hepatol. 2020;43:415-417.

    April 2020
  74. POUS S, Frasson M, Jimenez R, Pamies J, et al
    Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.
    Gastroenterol Hepatol. 2020;43:179-187.
    PubMed     Abstract available

    March 2020
  75. CASAS DEZA D, Garcia Lopez S, Lafuente Blasco M, Vicente Lidon R, et al
    Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
    Gastroenterol Hepatol. 2020;43:126-132.
    PubMed     Abstract available

    January 2020
  76. GELY C, Marin L, Gordillo J, Manosa M, et al
    Impact of pain associated with the subcutaneous administration of adalimumab.
    Gastroenterol Hepatol. 2020;43:9-13.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.